← Human Trials & Peer-Reviewed Studies
The effect of vitamin D on recurrence of uterine fibroids: A randomized, double-blind, placebo-controlled pilot study.
Plain-language guide to PMID 35092948 (2022): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 35092948
- Journal
- Complementary therapies in clinical practice
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Vahdat M et al. (7 authors)
- DOI
- 10.1016/j.ctcp.2022.101536
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The researchers aimed to investigate the effect of vitamin D supplementation on the recurrence of UFs.
Who Took Part
By PubMed's age tags, the people studied were adults, women only.
Both groups were followed and compared in regard of the primary outcomes of the study, which were recurrence rates, size, and numbers of UFs based on three-dimensional transvaginal ultrasound investigation (3D-TVS).
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and pilot study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Data analysis was performed by the intention-to-treat (ITT) approach.
What Was Measured
Topics PubMed links to this paper include Leiomyoma, Pilot Projects, Uterine Neoplasms, Vitamin D and Vitamins.
The authors tagged it with the keywords Recurrence and uterine myomectomy.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (Complementary therapies in clinical practice), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.